Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 16/20 | 0.67 |
| ▸ | CTSS | P25774 | 11/20 | 0.67 |
| ▸ | KIF11 | P52732 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3569976 | 0.83 | CTSK (0.64) | CTSKCTSSKIF11KCNH2CTSL | |
| SCHEMBL4453855 | 0.80 | CTSK (1.00) | CTSKCTSS | |
| SCHEMBL3568417 | 0.80 | ALDH1A1 (0.50) | CTSKCTSS | |
| SCHEMBL3558614 | 0.79 | CTSK (0.60) | CTSKCTSSKIF11KCNH2CTSL | |
| SCHEMBL1509844 | 0.79 | CTSK (0.62) | CTSKCTSS | |
| SCHEMBL16804872 | 0.79 | RAD51 (0.47) | CTSKCTSSKIF11RAD51ADORA3 | |
| SCHEMBL15533905 | 0.76 | RAD51 (0.45) | CTSKCTSSKIF11RAD51ADORA3 | |
| SCHEMBL19262265 | 0.76 | RAD51 (0.45) | CTSKCTSSKIF11RAD51ADORA3 | |
| SCHEMBL3561445 | 0.76 | ALDH1A1 (0.47) | CTSKCTSSKIF11RAD51ADORA3 | |
| SCHEMBL16005299 | 0.76 | KIF11 (0.61) | CTSKCTSSKIF11KCNH2RAD51 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200289508-A1 | NOVEL PYRIMIDINYL-DIAZOSPIRO COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2020-09-17 | — | — | US | disclosed |
| US-10010551-B2 | Pyrimidinyl-diazospiro compounds | Convergence Pharmaceuticals Limited (GB) | 2018-07-03 | — | — | US | disclosed |
| US-20170304303-A1 | Novel Pyrimidinyl-DiazoSpiro Compounds | Convergence Pharmaceuticals Limited (GB) | 2017-10-26 | — | — | US | disclosed |
| US-20170304303-A1 | Novel Pyrimidinyl-DiazoSpiro Compounds | Convergence Pharmaceuticals Limited (GB) | 2017-10-26 | — | — | US | disclosed |
| US-9737536-B2 | Pyrimidinyl-diazospiro compounds | Convergence Pharmaceuticals Limited (GB) | 2017-08-22 | — | — | US | disclosed |
| US-9737536-B2 | Pyrimidinyl-diazospiro compounds | Convergence Pharmaceuticals Limited (GB) | 2017-08-22 | — | — | US | disclosed |
| EP-3106464-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2016-12-21 | — | — | EP | disclosed |
| US-20160263115-A1 | Novel Pyrimidinyl-DiazoSpiro Compounds | Convergence Pharmaceuticals Limited (GB) | 2016-09-15 | — | — | US | disclosed |
| US-20160263115-A1 | Novel Pyrimidinyl-DiazoSpiro Compounds | Convergence Pharmaceuticals Limited (GB) | 2016-09-15 | — | — | US | disclosed |
| EP-2861594-B1 | NOVEL COMPOUNDS | CONVERGENCE PHARMACEUTICALS (GB) | 2016-08-24 | — | — | EP | disclosed |
| WO-2013175206-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2013-11-28 | — | — | WO | disclosed |
| EP-2468727-A1 | Pyridine and pyrimidine derivatives as MGLUR2 antagonists | F. Hoffmann-La Roche AG (CH) | 2012-06-27 | — | — | EP | disclosed |
| CN-102516161-A | Pyridine and pyrimidine derivatives as mglur2 antagonists | HOFFMANN LA ROCHE | 2012-06-27 | — | — | CN | disclosed |
| US-8183262-B2 | Central nervous system disorders; metabotropic glutamate receptors (mGluR); 2-(4-Pyridin-3-yl-imidazol-1-yl)-4-trifluoromethyl-6-(4-trifluoromethyl-phenyl)-pyrimidine | HOFFMANN-LA ROCHE INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-7642264-B2 | Phenyl-substituted pyrimidine derivatives as mGluR antagonists | HOFFMAN-LA ROCHE INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20090318474-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS | GATTI MCARTHUR SILVIA | 2009-12-24 | — | — | US | disclosed |
| CN-101415681-A | Pyridine and pyrimidine derivatives as mGluR2 antagonists | HOFFMANN LA ROCHE (CH) | 2009-04-22 | — | — | CN | disclosed |
| EP-2001849-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2008-12-17 | — | — | EP | disclosed |
| US-20070232583-A1 | Pyridine and pyrimidine derivatives as mGIuR2 antagonists | HOFFMANN-LA ROCHE INC. | 2007-10-04 | — | — | US | disclosed |
| WO-2007110337-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232583-A1 | Pyridine and pyrimidine derivatives as mGIuR2 antagonists | P2RX2, P2RY2, P2RX1 | CTSK 3987/4885CTSS 4230/4885KIF11 3845/4885 |
| US-20200289508-A1 | NOVEL PYRIMIDINYL-DIAZOSPIRO COMPOUNDS | TRPV1, KCNJ2, KCNN2 | CTSK 4404/4885CTSS 4388/4885KIF11 4014/4885 |
| US-20090318474-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS | GRM2, GRM1, GRM3 | CTSK 4317/4885CTSS 4655/4885KIF11 3339/4885 |
| US-20160263115-A1 | Novel Pyrimidinyl-DiazoSpiro Compounds | TRPV1, KCNJ2, SCN1A | CTSK 4368/4885CTSS 4443/4885KIF11 4088/4885 |
| US-10010551-B2 | Pyrimidinyl-diazospiro compounds | KCNJ2, TRPV1, SCN2A | CTSK 4405/4885CTSS 4417/4885KIF11 4333/4885 |
| US-20170304303-A1 | Novel Pyrimidinyl-DiazoSpiro Compounds | TRPV1, KCNJ2, KCNN2 | CTSK 4442/4885CTSS 4425/4885KIF11 4176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.